Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study - 09/08/11
, Mary A. Whooley, MD b, c, f, David V. Glidden, PhD c, Ludmila Pawlikowska, PhD d, Jonathan G. Zaroff, MD e, Jeffrey E. Olgin, MD a, dRésumé |
Background |
Previous studies suggest that markers of inflammation are elevated in patients with atrial fibrillation (AF). However, because inflammation has been implicated in contributing to risk of both AF and coronary artery disease (CAD), which are often present in the same populations, it is important to control for confounding by the presence of CAD. We therefore examined several biomarkers of inflammation and ultimately genotyped IL-6 polymorphisms in patients with AF in a cohort of subjects with known CAD.
Methods |
We performed a cross-sectional analysis of 971 participants in the Heart and Soul Study, 46 of whom had AF. Interleukin-6, C-reactive protein, tumor necrosis factor-α, CD-40 ligand, monocyte chemoattractant protein-1, and fibrinogen levels were measured.
Results |
In both unadjusted and adjusted analyses, IL-6 was the only biomarker significantly associated with AF (median IL-6 3.76 and 2.52 pg/mL in those with and without AF, respectively, P = .0005; adjusted odds ratio 1.77, P = .032). The IL-6−174CC genotype was significantly associated with the presence of AF in the adjusted analysis (odds ratio 2.34, P = .04) and with higher IL-6 levels (P = .002).
Conclusions |
In this cohort of subjects with CAD, AF was significantly associated with elevated IL-6 levels and the IL-6−174CC genotype. No associations were found with other biomarkers, including C-reactive protein. This suggests that IL-6 is a uniquely important mediator in the pathophysiology of AF.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: This work was made possible by Grant Number K12 RR024130 (GMM) from the National Center for Research Resources (NCRR), a component of the NIH and NIH Roadmap for Medical Research; American Heart Association Western States Affiliate Beginning Grant-in-Aid Award (GMM); the National Heart, Lung, and Blood Institute grant RO1-HL072854 (J.E.O.); and NIH. The Heart and Soul Study was funded by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program), Washington, DC; the National Heart Lung and Blood Institute grant R01 HL079235; the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholar Program), Princeton, NJ; the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), New York, NY; and the Ischemia Research and Education Foundation, San Bruno, CA. |
Vol 155 - N° 2
P. 303-309 - février 2008 Retour au numéro
Article précédent
- Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) and Aggrastat to Zocor (A to Z) trials
- Dalton S. McLean, Shmuel Ravid, Michael Blazing, Bernard Gersh, Amy Shui, Christopher P. Cannon
- Atrial fibrillation and obesity—results of a meta-analysis
- Nikolas Wanahita, Franz H. Messerli, Sripal Bangalore, Apoor S. Gami, Virend K. Somers, Jonathan S. Steinberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?